1. Home
  2. LFMD vs PLYX Comparison

LFMD vs PLYX Comparison

Compare LFMD & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LifeMD Inc.

LFMD

LifeMD Inc.

HOLD

Current Price

$4.76

Market Cap

236.7M

Sector

Health Care

ML Signal

HOLD

PLYX

Polaryx Therapeutics Inc. Common Stock

N/A

Current Price

$3.95

Market Cap

271.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LFMD
PLYX
Founded
1994
2014
Country
United States
United States
Employees
384
N/A
Industry
Medical/Nursing Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
236.7M
271.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
LFMD
PLYX
Price
$4.76
$3.95
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
1
Target Price
$9.14
$10.00
AVG Volume (30 Days)
1.3M
106.6K
Earning Date
05-06-2026
05-22-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$17.52
N/A
Revenue Next Year
$18.73
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.60
$2.20
52 Week High
$15.34
$9.18

Technical Indicators

Market Signals
Indicator
LFMD
PLYX
Relative Strength Index (RSI) 56.22 34.57
Support Level $3.39 $2.58
Resistance Level $4.93 $7.29
Average True Range (ATR) 0.36 0.57
MACD -0.00 -0.21
Stochastic Oscillator 47.16 21.70

Price Performance

Historical Comparison
LFMD
PLYX

About LFMD LifeMD Inc.

LifeMD Inc is a patient-centric, direct-to-patient healthcare company providing a high-quality, cost-effective, and convenient way for patients to access virtual medical care and pharmacy services. The Company's portfolio of brands within continuing operations is now managed as a single operating segment, Telehealth. Telehealth platform integrates core capabilities, includes: A nationwide pharmacy network, A wholly-owned commercial pharmacy, A fully integrated patient care center, A direct-to-patient marketing infrastructure for acquisition and retention, and AI-enabled clinical and operational technologies.

About PLYX Polaryx Therapeutics Inc. Common Stock

Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.

Share on Social Networks: